Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MRNS | US
0.11
6.32%
Healthcare
Biotechnology
30/06/2024
18/10/2024
1.85
1.73
1.87
1.73
Marinus Pharmaceuticals Inc. a pharmaceutical company focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone) an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors a target for its anti-seizure antidepressant and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders such as PCDH19-related epilepsy and tuberous sclerosis complex. Marinus Pharmaceuticals Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co. Ltd. The company was incorporated in 2003 and is headquartered in Radnor Pennsylvania.
View LessPositive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
70.6%1 month
90.3%3 months
81.1%6 months
72.6%-
-
3.17
-2.03
1.10
-34.47
2.95
-
-128.66M
101.91M
101.91M
-
-375.94
-
32.50
-2.99K
4.95
5.87
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.23
Range1M
0.47
Range3M
0.92
Rel. volume
1.50
Price X volume
2.06M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
AVTX | AVTX | Biotechnology | 11.18 | 108.45M | 7.50% | n/a | -80.47% |
CIBUS GLOBAL LTD. | CBUS | Biotechnology | 3.59 | 105.87M | 3.76% | n/a | 81.33% |
Oncolytics Biotech Inc. (USA) | ONCY | Biotechnology | 1.35 | 103.76M | 5.47% | n/a | 0.00% |
Prelude Therapeutics Incorporated | PRLD | Biotechnology | 1.9 | 103.74M | -1.04% | n/a | 9.99% |
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.57 | 102.78M | 3.29% | n/a | 1.45% |
Leap Therapeutics Inc | LPTX | Biotechnology | 2.675 | 102.36M | 14.81% | n/a | 0.73% |
Coherus BioSciences Inc | CHRS | Biotechnology | 0.8829 | 101.72M | 4.09% | n/a | -354.71% |
INmune Bio Inc | INMB | Biotechnology | 5.11 | 101.34M | 2.20% | n/a | 14.65% |
Genenta Science S.p.A | GNTA | Biotechnology | 5.5 | 100.19M | -4.51% | n/a | 0.00% |
Agenus Inc | AGEN | Biotechnology | 4.62 | 99.66M | 1.09% | n/a | -170.56% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.28 | 92.70M | 0.72% | 5.27 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.48 | 90.67M | 0.91% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -34.47 | 0.53 | Cheaper |
Ent. to Revenue | 2.95 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 3.17 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 81.12 | 72.92 | Par |
Debt to Equity | -2.03 | -1.24 | Cheaper |
Debt to Assets | 1.10 | 0.25 | Expensive |
Market Cap | 101.91M | 3.78B | Emerging |